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Northridge, CA, USAA B S T R A C TDiabetes is a key driver in the rise of noncommunicable diseases
globally. It causes expensive and burdensome short- and long-term
complications, with both an economic and social impact. In many
countries, however, access to care and disease management in type 1
diabetes is suboptimal, increasing the risk for complications. In 2011,
Project Baiterek was initiated as a collaborative effort between the
Kazakhstan Ministry of Health, industry (Medtronic Plc), local physi-
cians, and the Diabetes Association of the Republic of Kazakhstan to
enhance patient access to continuous subcutaneous insulin infusion
(CSII) therapy. It was the ﬁrst countrywide project to provide equity and
universal access to insulin pump therapy among children with type 1
diabetes, increasing pump use from zero to two-thirds of this popula-
tion in less than 3 years. The project also involved instigating
longitudinal data collection, and long-term clinical outcomes continue
to be monitored. Here, we provide an overview of the clinical, quality-ee front matter & 2015 Published by Elsevier Inc.
(ISPOR).
.1016/j.vhri.2015.09.002
lmer@ossianconsulting.com.
ndence to: Jayne Smith-Palmer, Ossian Health Econof-life, and economic outcomes to date associated with providing CSII
therapy to children with type 1 diabetes in Kazakhstan. Initial clinical
data show that CSII therapy improved clinical outcomes and quality of
life for patients entered into the program and that CSII therapy was
cost-effective relative to multiple daily injection therapy. The positive
outcomes of Project Baiterek provide a template for similar patient
access programs in other settings, and its framework could be adapted
to initiatives to change health care infrastructures and standards of
care for other noncommunicable diseases.
Keywords: continuous subcutaneous insulin infusion, cost-
effectiveness, hypoglycemia, insulin pumps, Kazakhstan, patient access
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Pharmacoeconomics and Outcomes Research (ISPOR).Problem Statement: Care and Access to Care for Type
1 Diabetes is Suboptimal
Burden of Disease
Globally, there are approximately half a million children with type
1 diabetes [1], including a large number without access to high-
quality pediatric diabetes care. The treatment of type 1 diabetes
involves a complex regimen of exogenous insulin administration
and the frequent measurement of blood glucose levels to attempt
to improve overall glucose control. As a result, the long-term
outlook for children with this disease varies substantially across
settings because of the variability in resources, treatment options,
and knowledge and experience of health care providers.The World Health Organization has reported that diabetes
(including both type 1 and type 2) is 1 of the 10 leading causes of
death in middle- and upper-income countries [2]. Suboptimal
blood glucose control in patients with diabetes results in life-
threatening acute and long-term complications (e.g., renal failure
requiring dialysis) that are devastating to the individual and
costly to the health care system. Indeed, direct medical costs
associated with diabetes and its complications exceeded €90
billion in 2012 in France, Italy, Germany, Spain, and the United
Kingdom alone (2010 €) [3]. In contrast, optimal blood glucose
management, such as that which can be achieved by continuous
subcutaneous insulin infusion (CSII) therapy and that limits the
amount of time spent in hypoglycemia and hyperglycemia, has
been shown to reduce complication rates, improve patienton behalf of International Society for Pharmacoeconomics and
omics and Communications GmbH, Bäumleingasse 20, 4051 Basel,
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tries and health policy makers must allocate limited funds to
maximize the public’s health and often make decisions whose
beneﬁts may not be immediately appreciated, particularly if they
involve changing health care infrastructure. Providing a strong
evidence base for such initiatives can help minimize risk as
projects unfold because interim outcomes and projected savings
can be regularly monitored.
Barriers to Optimal Diabetes Care
In addition to clinical and economic implications, diabetes has a
strong societal impact. It is well documented that diabetes has a
negative impact on quality of life (QOL), especially in children.
Indeed, in some countries, children with type 1 diabetes are
automatically registered as handicapped and sometimes refused
entry to mainstream schools [4,5], which can limit their full
participation in society. Because type 1 diabetes is often a challeng-
ing disease to treat and requires specialized expertise, many
countries do not have the infrastructure to optimize diabetes
management. Barriers include a lack of specialists and localization
of specialists in large urban areas, meaning that patients often have
to travel long distances for treatment; for example, in Kazakhstan
the number of endocrinologists per 100,000 population is approx-
imately sixfold lower in rural areas than in urban areas [6,7]. Other
barriers include a lack of disease knowledge among both patients
and care providers as well as insufﬁcient training on innovations
and advanced technologies and treatments. For example, before the
initiation of Project Baiterek, there were only four endocrinologists
in Kazakhstan who had received training in the use of insulin
pumps. Moreover, in some settings, epidemiologic data and long-
term patient outcomes are often difﬁcult to track owing to a lack of
regionally or nationally organized patient registers. Changes in
infrastructure, including the provision of specialist training and
the dissemination of information to both physicians and patients,
are necessary to improve the provision of care of type 1 diabetes,
and these strategies may be applicable to other chronic noncom-
municable diseases (NCDs).Diabetes Therapy Solution: Optimizing Patient
Outcomes Through Innovation and Technology
For survival, patients with type 1 diabetes are dependent on a
lifetime of exogenous insulin administration, either in the form of
multiple daily injection (MDI) therapy or with insulin pumps.
Several previous studies have demonstrated that CSII therapy
leads to improved glycemic control and fewer hypoglycemic
events versus MDI therapy [8]. Good glycemic control, as indicated
by hemoglobin A1c (Hb A1c) within the target range (o7.5% in
children and o7.0% in adults [9]), is the single most effective way
to prevent and delay costly long-term diabetes-related complica-
tions as well as acute complications, including hypoglycemic
events and ketoacidosis [10–12]. CSII therapy represents a partic-
ularly useful treatment option for pediatric patients with type 1
diabetes, especially those with poor glycemic control or frequent
or problematic hypoglycemic events. It offers more ﬂexibility and
freedom in terms of timing of meals and activity than does MDI
therapy. In the United States, approximately 40% of patients with
type 1 diabetes use CSII therapy [13]. In much geography around
the world, however, the use of CSII therapy is very low due to cost
and lack of trained health care providers. These barriers are
present even in developed countries, such as the United Kingdom
and France, where the use of CSII therapy in pediatric patients
with type 1 diabetes is less than 20%, and even lower in adults
[13,14]. Analyses from the payer perspective across multiple
settings have shown that the initial cost is mitigated by thelong-term reduction in cost relative to MDI therapy, due to the
lower incidence of diabetes-related complications [15–18].Project Baiterek: A Patient Access Scheme in
Kazakhstan
In 2011 in Kazakhstan, a unique public private partnership
(Project Baiterek) was initiated to improve the clinical outcomes
and QOL in children with diabetes, while reducing the incidence
of costly acute and long-term diabetes-related complications. In
2011, there were approximately 11,400 adults and 1500 children
(aged 1–18 years) with type 1 diabetes [19], mainly treated with
MDI regimens. In addition, in Kazakhstan, diabetes care was
generally underfunded, there was a variable level of qualiﬁcation
of the country’s endocrinologists, and there were signiﬁcant
differences in the quality of care between major cities and
regional centers. Diabetes patients suffered from social stigma
and poor QOL. They were considered “invalids,” which limited
their educational and professional opportunities.
Project Baiterek as a Collaborative Project
Project Baiterek was launched as a collaborative effort between
the Kazakhstan Ministry of Health, the Diabetes Association of
the Republic of Kazakhstan (DARK), Medtronic Plc, and local
endocrinologists.
Ministry of Health Involvement
As part of the project, the Kazakhstan Ministry of Health secured
funding to purchase 790 Paradigm Veo insulin pumps (Medtronic,
Northridge, CA) for children aged 5 to 15 years, together with
rapid-acting insulin analogues, consumables (insulin pump res-
ervoirs and infusion sets), blood glucose meters, and 30 blood
glucose test strips per patient per month.
Patient Recruitment
The project was conducted on a nationwide basis, with one to three
local physicians identiﬁed from each of the 17 regions of Kazakh-
stan, and per-site enrollments ranged from 9 to 85 patients (Fig. 1).
For initial inclusion, patients were required to be aged 5 to 15 years
with a diagnosis of type 1 diabetes. All patients received intensive
CSII therapy training with health care providers and Medtronic and
a long-term treatment plan including frequent follow-up and
adjustment of therapy when needed. All patients received follow-
up appointments at 3-month intervals, and clinical data collection
is ongoing, which will enable a longitudinal assessment of patient
outcomes. A 24-hour patient support helpline was also established
for the use of patients, parents, and care providers.
Care Provider Involvement
Between one and three physicians from each of the 17 regions of
Kazakhstan participated in the project and in total 266 health care
professionals received training on the use of CSII therapy (compared
with 4 health care providers before the initiation of the project).
Medtronic provided specialist training for physicians on pump
therapy, created standardized patient training materials, established
clinical monitoring procedures, and scaled patient support and
operations. Advanced CSII therapy training was initially provided
by leading pediatric endocrine experts at diabetes centers in Israel,
Slovenia, Russia, and the United States, and followed by recurrent
training sessions in Kazakhstan, Austria, and the United States.
Medtronic also supported local endocrinologists with the collection
of clinical (blood glucose levels, Hb A1c, and rates of hypoglycemia
and diabetic ketoacidosis), QOL, and health economic data to assess
the long-term impact of Project Baiterek.
Fig. 1 – Number of insulin pumps in Project Baiterek according to region in 2013. From Toktarova et al. [20].
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DARK collaborated with the Ministry of Health and Medtronic to
disseminate information related to the beneﬁts associated with the
use of insulin pump therapy and to raise awareness of the burden
and the societal impact of type 1 diabetes. DARK was also involved
in raising awareness of the successful collaboration between the
Patient Advocacy Group, the Ministry of Health, health care pro-
fessionals, and the insulin pump manufacturer (Medtronic).
Preliminary Findings from Project Baiterek
A total of 790 children, corresponding to more than two-third of
pediatric patients aged 5 to 15 years with type 1 diabetes in
Kazakhstan, have been enrolled in Project Baiterek (Fig. 1 [20]).
Analysis of 6-month data showed that the initiation of CSII
therapy resulted in improved glycemic control. Decreases in theFig. 2 – Change in six quality-of-life domains in pediatric patien
6 months on CSII.frequency of severe hypoglycemic events and diabetic ketoacidosis,
as well as improvements in all domains of health-related QOL,
were also reported. More speciﬁcally, improvements of more than
100% from baseline in the QOL domains of social limitations, life
interference, general satisfaction, ﬂexibility, and convenience
were reported at 6 months (Fig. 2). Twenty-four instances of
severe hypoglycemic events were reported before switching to
CSII therapy and three events after initiating CSII therapy; the
corresponding numbers for ketoacidosis events were 175 and 65,
respectively. In addition, for those patients with baseline Hb A1c
levels of 7.5% or more (mean Hb A1c level of 10.5%) experienced a
mean decrease of 0.9% at 6 months (Fig. 3) [21].
The clinical beneﬁts in this cohort (patients with an Hb A1c
level of Z7.5% at baseline) combined with the local (Kazakhstan-
speciﬁc) costs of intervention and complications have been
entered into the CORE Diabetes Model, a peer-reviewed, validatedts with type 1 diabetes in Kazakhstan from baseline to
Fig. 3 – HbA1c at baseline and at 6 months. HemoglobinA1c, Hb A1c
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niques to describe the long-term incidence and progression of
diabetes-related complications [22]. Because the costs of physi-
cian training, patient training materials, marketing materials, and
set-up of infrastructure changes required for longitudinal clinical
data collection were borne by Medtronic, the cost-effectiveness
analysis (in which cost inputs consisted of Kazakhstan-speciﬁc
costs of CSII therapy together with costs of acute and long-term
complications) represents the overall cost-effectiveness of Project
Baiterek from the national payer perspective. The results of the
cost-effectiveness analysis showed that over the lifetime of the
cohort, the Hb A1c reduction would be projected to lead to a
reduction in the cumulative incidence of proliferative diabetic
retinopathy, blindness, and end-stage renal disease by 25.3%,
5.6%, and 28.3%, respectively (Table 1) and an increase of 3.58
years in undiscounted life expectancy for CSII therapy versus MDI
therapy [21]. Continued clinical data collection will allow for long-
term longitudinal assessment of patient outcomes.Short- and Long-Term Impact of Project Baiterek
Preliminary clinical results from Project Baiterek showed
improved glycemic outcomes and QOL, as well as a reduced
incidence of severe, costly, and potentially life-threatening hypo-
glycemic events and diabetic ketoacidosis.
The long-term cost-effectiveness analysis showed that in the
context of the Kazakh health care system, CSII therapy was cost-
effective relative to MDI therapy due to improved glycemicTable 1 – Summary of cost-effectiveness modeling ﬁndin
Outcome CSII
Quality-adjusted life expectancy (QALYs) 14.56
Direct costs (Kazakhstani Tenge) 9,225,69
Incremental cost-effectiveness ratio
Reduction in cumulative incidence of complications with CSII (%)
Proliferative diabetic retinopathy
Blindness
End-stage renal disease
Gross proteinuria
Data from Roze et al. [22].
CSII, continuous subcutaneous insulin infusion; MDI, multiple daily injecontrol [22], which itself is proven to reduce the incidence of
costly diabetes-related complications including cardiovascular
disease, renal disease, ophthalmic complications, and diabetic
foot problems [10–12] (Table 1).
In addition to the direct clinical and QOL beneﬁts, the long-term
implications of the project include a successful change in the infra-
structure of pediatric diabetes care, with the implementation of best
management practices for patients. The collection of clinical data
remains ongoing and will examine the long-term clinical and
economic impact of improved Hb A1c and reduced incidence of
hypoglycemic events in this setting. Previous studies in other settings
have shown that the clinical beneﬁts associated with switching to
CSII therapy are sustained for periods of up to 7 years [23,24].
The comprehensive nature of Project Baiterek has enabled the
Kazakh pediatric endocrinologist community to meet interna-
tional standards, such as the UK National Institute for Health and
Care Excellence (NICE) guidelines. These guidelines state that
insulin pump therapy should be initiated only in centers with
sufﬁcient infrastructure and specialist training [25]. In addition,
Kazakh public health authorities have been able to advance
competencies and knowledge in health economics and modeling,
which can be applied to ongoing and future initiatives.Project Baiterek as a Pioneering Patient Access
Scheme
Over a 3-year time horizon, Project Baiterek has resulted in
substantial clinical improvements for children with type 1gs.
MDI Difference
13.34 1.21
4 4,459,297 4,766,396
3,935,375 KZT per QALY gained
25.3
5.6
28.3
17.7
ction; QALY, quality-adjusted life-year.
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of reduced diabetes-related complications and reduction in direct
medical costs. Before this project, insulin pumps were rarely, if
ever, used in Kazakhstan. As of March 2014, more than two-thirds
of the patients aged 5 to 15 years with type 1 diabetes (n ¼ 790) in
Kazakhstan were using CSII therapy, which now represents the
standard of care in this setting. The uptake of insulin pump
therapy in Kazakhstan exceeds that of many other countries.
Indeed, in the United Kingdom, only 19% of pediatric and 6% of
adult patients with type 1 diabetes currently use CSII therapy,
which is below the expectations of NICE [26].
Moreover, this project has shown that through collaboration
and successful partnerships between industry, payers, endocri-
nologists, and patient advocacy groups, nationwide changes in
infrastructure and patient management practices can be estab-
lished and serve as a framework for other NCDs. Two of the
targets in the World Health Organization Global Action Plan for
the Prevention and Control of NCDs and the Kazakhstan Alliance
against NCDs include a 25% relative reduction in premature
mortality from NCDs by 2025 and an 80% availability of basic
and essential medicines [27,28]. The improved outcomes and care
for type 1 diabetes in Kazakhstan are likely to contribute to
meeting these goals, and, moreover, the project provides a road-
map that can be used to help achieve these goals for other NCDs.
Project Baiterek could be considered to be a world-leading
example in terms of the swift and successful implementation of
changes in health care infrastructure and standards of care, with
successful clinical and economic outcomes. It is likely that the buy-
in and close collaboration between the stakeholders was pivotal to
the success of the project and that projects involving partnerships
across governments, industry, patient advocacy groups, and local
health care providers may be more likely than isolated initiatives to
succeed. For example, in the United Kingdom, where insulin pump
use falls below NICE target ﬁgures, funding alone does not ensure
uptake of technology. The involvement of patient associations/
advocacy groups to enhance patient access was also likely a key
component of success in Project Baiterek. These groups play an
important role in disseminating information to patients, and
encouraging patient participation and compliance with new initia-
tives, and often represent a powerful voice in terms of lobbying
policymakers for the introduction of new interventions.
There is little doubt that similar projects can be used in other
regions around the world where there are barriers to insulin
pumps and technology to promote patient access to CSII therapy.
This project has provided policymakers with a model that they
can use to justify investing limited funds in pediatric diabetes.
Regions can follow the example of Kazakhstan, run a pilot
scheme to determine feasibility, and then bring the project to
scale if that is realistic and manageable based on local budget,
needs, and limitations. By using a stepwise approach, policy-
makers can better manage priorities and planning. The initial
cost associated with insulin pumps can be a signiﬁcant barrier to
uptake, particularly when there is patient participation in pay-
ment. The experience in Kazakhstan, however, suggests that the
initial costs of insulin pumps can be mitigated by cost savings in
the long-term associated with improved glycemic control and the
resulting lower incidence of diabetes-related complications. Cost-
effectiveness analyses conducted in several other settings have
consistently shown that in the long-term, CSII therapy is cost-
effective versus MDI therapy [15–18]. The consistency of ﬁndings
of previous cost-effectiveness analysis and improved clinical
outcomes present a robust and persuasive argument to payers
to endorse the use of CSII therapy in pediatric patients with type
1 diabetes, particularly when combined with changes in infra-
structure and training that are also likely to beneﬁt adults with
poorly managed type 1 diabetes.Conclusions
Overall, Project Baiterek, which involved the widespread intro-
duction of CSII therapy in pediatric patients with type 1 diabetes
in Kazakhstan, was both effective and cost-effective and has
improved the lives of more than two-thirds of pediatric patients
with type 1 diabetes in the country. It advanced specialist
training to health care providers, facilitated longitudinal data
collection, and established long-term improvements in health
care infrastructure. Presently, there are many settings in which
standards of care for type 1 diabetes and other NCDs could be
improved. The example set by Kazakhstan warrants a call to
action for others to replicate the success of Project Baiterek for
type 1 diabetes and other NCDs. The success of this project
provides an example of a successful real-world patient access
scheme that can be used in other regions around the world and
for other NCDs.
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